Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 as a target for anticancer drug development.

Jean-Baptiste Méric1, Sylvie Rottey, Ken Olaussen

  • 1Service d'Oncologie Médicale, Hôpital Pitié-Salpêtrière, 47 Boulevard de l'hôpital, 75651 Paris Cedex 13, France. jean-baptiste.meric@psl.ap-hop-paris.fr

Critical Reviews in Oncology/Hematology
|March 15, 2006
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Evolution of cancer treatment modalities].

La Revue du praticien·2024
Same author

[Cancers in France: 10 key messages].

La Revue du praticien·2024
Same author

[Cancer epidemiology, risk factors, prevention and screening].

La Revue du praticien·2024
Same author

Improve the management of cancer-related cognitive impairment in clinical settings: a European Delphi study.

Journal of cancer survivorship : research and practice·2023
Same author

[Covid-19 and cancers: how to do better in a crisis?]

La Revue du praticien·2023
Same author

Estimation of Oncologic Surgery Case Volume Before and After the COVID-19 Pandemic in France.

JAMA network open·2023

Cyclooxygenase-2 (COX-2) inhibitors show promise in preventing and treating solid tumors by targeting cancer cell pathways. Further research is ongoing to fully understand their role in various cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cyclooxygenase-1 and -2 (COX-1/COX-2) enzymes initiate prostaglandin synthesis involved in pathophysiological processes.
  • The role of COX-2 in carcinogenesis, influencing apoptosis, angiogenesis, and invasion, is increasingly recognized.
  • While typically upregulated in cancer, some cancers like prostate and breast exhibit low COX-2 expression, necessitating further investigation.

Purpose of the Study:

  • To review the evidence for cyclooxygenase (COX) inhibitors, including non-steroidal anti-inflammatory drugs (NSAIDs) and selective COX-2 inhibitors, in cancer prevention and treatment.
  • To explore the mechanisms by which NSAIDs affect cancer cells, beyond COX enzyme inhibition.
  • To assess the potential of targeting the COX-2 pathway as a therapeutic strategy for solid tumors.

Related Experiment Videos

Main Methods:

  • Review of epidemiological trials on aspirin and NSAID users.
  • Analysis of clinical trials in familial adenomatosis polyposis syndrome.
  • Examination of preclinical studies on combination treatments (chemotherapy, radiotherapy, EGFR inhibitors with COX inhibitors).
  • Evaluation of early clinical trials combining chemotherapy with COX-2 inhibitors.

Main Results:

  • Epidemiological and clinical studies suggest NSAIDs and COX inhibitors may benefit malignancy development and growth, particularly in colorectal polyps.
  • Preclinical studies demonstrate promising results for combination therapies involving COX inhibitors with chemotherapy, radiotherapy, or EGFR inhibitors.
  • Early clinical trials combining chemotherapy with COX-2 inhibitors show encouraging outcomes in advanced and neoadjuvant cancer settings.

Conclusions:

  • Targeting the COX-2 pathway represents a promising strategy for the prevention and treatment of solid tumors.
  • NSAID effects in cancer involve interactions with downstream COX-2 effectors, not solely COX enzyme inhibition.
  • Ongoing clinical trials are crucial to fully elucidate the role of COX-2 in cancer and optimize therapeutic strategies.